Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ladprao General Hospital PCLBKK:LPH-R 70 3-Year EBITDA Growth Rate is -3.70% as of Jun. 2026. GuruFocus rates BKK:LPH-R with a GF Score™ of 70/100 and a GF Value™ of ฿4.62 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 523 Healthcare Providers & Services companies, Ladprao General Hospital PCL ranks worse than 75.14% on this metric.
During the past 12 months, Ladprao General Hospital PCL's average EBITDA Per Share Growth Rate was 6.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -3.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -1.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 7.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ladprao General Hospital PCL was 36.90% per year. The lowest was -22.50% per year. And the median was 2.50% per year.
Ladprao General Hospital PCL (BKK:LPH-R) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Ladprao General Hospital PCL 3-Year EBITDA Growth Rate Related Terms
BKK:LPH-R vs HCA, THC, EHC: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Ladprao General Hospital PCL's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ladprao General Hospital PCL 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Ladprao General Hospital PCL's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Ladprao General Hospital PCL's 3-Year EBITDA Growth Rate falls into.
Ladprao General Hospital PCL 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -3.70% mean?
Ladprao General Hospital PCL (BKK:LPH-R) has a 3-Year EBITDA Growth Rate of -3.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ladprao General Hospital PCL and its competitors. According to the industry distribution chart, Ladprao General Hospital PCL ranks #393 out of 523 companies in the Healthcare Providers & Services industry, placing it in the top 75.1%.
Is Ladprao General Hospital PCL's 3-Year EBITDA Growth Rate too high?
Ladprao General Hospital PCL's current 3-Year EBITDA Growth Rate is -3.70%. Based on the distribution chart, Ladprao General Hospital PCL ranks #393 out of 523 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Ladprao General Hospital PCL has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ladprao General Hospital PCL's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Ladprao General Hospital PCL ranks #393 out of 523 companies for 3-Year EBITDA Growth Rate. This places Ladprao General Hospital PCL in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 9.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.90, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ladprao General Hospital PCL and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ladprao General Hospital PCL's current 3-Year EBITDA Growth Rate is -3.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ladprao General Hospital PCL stock overvalued right now?
Based on GuruFocus' analysis, Ladprao General Hospital PCL (BKK:LPH-R) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿4.62, compared to a current price of ฿3.58 — trading 22.6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is -3.70%. Ladprao General Hospital PCL's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Ladprao General Hospital PCL (BKK:LPH-R), the current 3-Year EBITDA Growth Rate is -3.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ladprao General Hospital PCL (BKK:LPH-R) Overvalued in 2026?
Based on GuruFocus' analysis, Ladprao General Hospital PCL stock appears to be undervalued.
The current stock price of ฿3.58 is trading 22.6% below its estimated GF Value™ of ฿4.62.
GuruFocus considers Ladprao General Hospital PCL to be Modestly Undervalued.
Key valuation signals for BKK:LPH-R:
3-Year EBITDA Growth Rate: -3.70%
GF Value™: ฿4.62 vs. price of ฿3.58 (22.6% below fair value)
No single metric tells the full story. See the BKK:LPH-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ladprao General Hospital PCL is principally engaged in the hospital business. It has two segments: Hospital, and Scientific testing &, Inspection & Quality System Certification. The Hospital segment includes hospital services, health care centers, and a service contract with the Social Security Office. The Scientific Testing & Inspection & Quality System Certification segment provides analytical and diagnostic services for food and agricultural, pharmaceutical, and environmental, covering product analysis, calibration of instruments, inspections, and certifications in accordance with quality systems and international standards. A majority of its revenue is generated from the Hospital segment. The company mainly operates in Thailand.
70GF Score
Get the complete analysis for BKK:LPH-R
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:LPH-R has been successfully added to your 
